PHARMACOSMOS A/S: Financial statements 2019
CVR: 15517085
Source: annual report 2019, Danish Business Authority
01/05/2018 – 30/04/2019
PHARMACOSMOS A/S (CVR 15517085) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 573,077,000 and a net result of DKK 102,068,000 compared with DKK 69,125,000 the year before. That is an increase of 5.7% compared with the year before. The profit margin was 17.8%. Equity in the 2019 report amounted to DKK 826,960,000. The solvency ratio was 63.6%. The company had 236 employees in the financial year.
- Revenue
- DKK 573,077,000
- Gross Profit
- DKK 317,995,000
- Profit/Loss
- DKK 102,068,000
- Equity
- DKK 826,960,000
- Total Assets
- DKK 1,300,417,000
- Employees
- 236
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 573.1M | 318M | 102.1M | 827M | 236 |
| 2018 | 542.2M | 314.5M | 69.1M | 720.8M | 208 |
| 2017 | 511.6M | 314.8M | 158.7M | 656.8M | 172 |
| 2016 | 448M | 254.5M | 102.7M | 547.7M | 111 |
| 2015 | - | 208.8M | 81.1M | 496.9M | 105 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of February 8, 2019, Jacob Tolstrup has joined the board of directors of PHARMACOSMOS A/S.
As of February 8, 2019, Axel Kierkegaard has left the board of directors of PHARMACOSMOS A/S.
About PHARMACOSMOS A/S
PHARMACOSMOS A/S is a Danish company of the type Aktieselskab based in Holbæk, founded in 1991. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named PHARMACOSMOS PHARMACEUTICALS A/S and SOLOCHEM A/S. The management consists of Tobias Sidelmann Christensen, Claes Christian Strøm and Henrik Parker. The board consists of Jacob Tolstrup (chair), Lars Christensen, Lars Green and Martin Holst Lange. The company is owned by PHARMACOSMOS HOLDING A/S. The company has 327 employees (2026). In 2026, the company reported revenue of DKK 2,176,000,000 and a net result of DKK 714,000,000 compared with DKK 1,622,000,000 the year before. Equity in the 2026 report amounted to DKK 2,775,000,000.
